Reuters logo
Biogen Idec profit rises as new multiple sclerosis drug shines
January 29, 2014 / 11:51 AM / in 4 years

Biogen Idec profit rises as new multiple sclerosis drug shines

Jan 29 (Reuters) - Biogen Idec Inc on Wednesday said fourth-quarter profit soared 57 percent, helped by strong sales of its new multiple sclerosis drug, Tecfidera.

The U.S. biotechnology company’s net profit rose to $457.3 million, or $1.92 per share, in the quarter ended Dec. 31, from $292.1 million, or $1.23 per share, a year earlier.

Excluding special items, Biogen earned $2.34 per share. Analysts on average expected $2.28 per share, according to Thomson Reuters I/B/E/S.

The high-profile multiple sclerosis drug had sales of $398 million for the period. Total sales rose 39 percent to $1.97 billion, beating the analysts’ average estimate of $1.93 billion.

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below